A Randomized Phase II Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Methotrexate
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ELDORANDO
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.
- 08 Aug 2017 Planned initiation date changed from 13 Jul 2017 to 31 Aug 2017.